0000899243-22-005213.txt : 20220208 0000899243-22-005213.hdr.sgml : 20220208 20220208160556 ACCESSION NUMBER: 0000899243-22-005213 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220204 FILED AS OF DATE: 20220208 DATE AS OF CHANGE: 20220208 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Brennan Aoife CENTRAL INDEX KEY: 0001714563 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37566 FILM NUMBER: 22601613 MAIL ADDRESS: STREET 1: 200 SIDNEY STREET, SUITE 320 STREET 2: C/O SYNLOGIC, INC. CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SYNLOGIC, INC. CENTRAL INDEX KEY: 0001527599 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 261824804 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 301 BINNEY STREET STREET 2: SUITE 402 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-401-9975 MAIL ADDRESS: STREET 1: 301 BINNEY STREET STREET 2: SUITE 402 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Mirna Therapeutics, Inc. DATE OF NAME CHANGE: 20110809 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-02-04 0 0001527599 SYNLOGIC, INC. SYBX 0001714563 Brennan Aoife C/O SYNLOGIC, INC. 301 BINNEY STREET, SUITE 402 CAMBRIDGE MA 02142 1 1 0 0 See Remarks Common Stock 2022-02-04 4 A 0 106920 0.00 A 284237 D Stock Option (right to buy) 1.95 2022-02-04 4 A 0 434160 0.00 A 2032-02-04 Common Stock 434160 434160 D The shares of restricted stock were granted on February 4, 2022, and will vest beginning on April 1, 2022 (the "Vesting Start Date") in four equal annual installments on each anniversary of the Vesting Start Date, subject to the Reporting Person continuing to provide services to the Issuer as Chief Executive Officer through each such vesting date. The option will vest and become exercisable in equal monthly installments for forty-eight months beginning on the grant date, which is February 4, 2022, subject to the Reporting Person continuing to provide services to the Issuer as Chief Executive Officer through each such vesting date. President and Chief Executive Officer /s/ Aoife Brennan 2022-02-08